title: Treating hepatocellular carcinoma with sorafenib in liver transplant patients: an initial experience.
abstract: Sorafenib has been approved for the treatment of advanced hepatocellular carcinoma (HCC). However, there are no data reported on its use in HCC patients with localized disease who have undergone orthotopic liver transplantation (OLT). Herein, we have reviewed our initial experience with 7 HCC patients who were candidates for OLT and were treated with sorafenib. Treating liver transplant patients with sorafenib appeared to be safe based upon our limited experience. There is a strong need for clinical trials to comprehensively study the safety of sorafenib before OLT.
authors.affiliation: Division of Organ Transplantation, Department of Surgery, University of Massachusetts Medical School, Worcester, Massachusetts 01655, USA. reza.saidi@umassmemorial.org
authors.forename: R F
authors.initials: RF
authors.lastname: Saidi
authors.forename: S A
authors.initials: SA
authors.lastname: Shah
authors.forename: A P
authors.initials: AP
authors.lastname: Rawson
authors.forename: St
authors.initials: S
authors.lastname: Grossman
authors.forename: B
authors.initials: B
authors.lastname: Piperdi
authors.forename: A
authors.initials: A
authors.lastname: Bozorgzadeh
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001557:Benzenesulfonates / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy* / Q000601:surgery; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy* / Q000601:surgery; D016031:Liver Transplantation; D008297:Male; D008875:Middle Aged; D009536:Niacinamide / Q000031:analogs & derivatives; D010671:Phenylurea Compounds; D011725:Pyridines / Q000627:therapeutic use*; D000077157:Sorafenib
chemical_list: D000970:Antineoplastic Agents; D001557:Benzenesulfonates; D010671:Phenylurea Compounds; D011725:Pyridines; D009536:Niacinamide; D000077157:Sorafenib